Will Idera Pharmaceuticals Inc (IDRA) Go Down Anytime Soon?

September 17, 2017 - By Dolores Ford

Investors sentiment increased to 3.31 in 2016 Q4. Its up 1.26, from 2.05 in 2016Q3. It is positive, as 9 investors sold Idera Pharmaceuticals Inc shares while 7 reduced holdings. 14 funds opened positions while 39 raised stakes. 96.26 million shares or 180.02% more from 34.38 million shares in 2016Q3 were reported.
Moreover, Commonwealth Equity Service has 0% invested in Idera Pharmaceuticals Inc (NASDAQ:IDRA). Natixis holds 3.15M shares or 0.05% of its portfolio. Barclays Public Ltd Com accumulated 0% or 1,953 shares. Deutsche Comml Bank Ag has invested 0% of its portfolio in Idera Pharmaceuticals Inc (NASDAQ:IDRA). The New York-based Citigroup has invested 0% in Idera Pharmaceuticals Inc (NASDAQ:IDRA). Geode Cap Mngmt Limited Liability has invested 0% of its portfolio in Idera Pharmaceuticals Inc (NASDAQ:IDRA). Gru stated it has 51,198 shares or 0% of all its holdings. Hollencrest Securities Limited Co, California-based fund reported 182,570 shares. D E Shaw And Company has invested 0% of its portfolio in Idera Pharmaceuticals Inc (NASDAQ:IDRA). Moreover, Laurion Mgmt L P has 0.01% invested in Idera Pharmaceuticals Inc (NASDAQ:IDRA). Two Sigma Securities Lc stated it has 0.01% in Idera Pharmaceuticals Inc (NASDAQ:IDRA). Mycio Wealth Partners Ltd Liability Com stated it has 0.05% of its portfolio in Idera Pharmaceuticals Inc (NASDAQ:IDRA). Blackrock Invest Mngmt Limited Company reported 367,938 shares. Millennium Mngmt Ltd Liability reported 463,024 shares stake. Art Advsrs Limited Com, New York-based fund reported 60,935 shares.

Since May 1, 2017, it had 0 insider buys, and 1 insider sale for $1.02 million activity. Pillar Invest Corp also sold $1.02M worth of Idera Pharmaceuticals Inc (NASDAQ:IDRA) shares.

The stock of Idera Pharmaceuticals Inc (NASDAQ:IDRA) is a huge mover today! The stock increased 5.50% or $0.11 on September 15, reaching $2.11. About 1.77M shares traded or 77.17% up from the average. Idera Pharmaceuticals Inc (NASDAQ:IDRA) has risen 21.13% since September 17, 2016 and is uptrending. It has outperformed by 4.43% the S&P500.
The move comes after 5 months positive chart setup for the $315.72M company. It was reported on Sep, 17 by Barchart.com. We have $2.28 PT which if reached, will make NASDAQ:IDRA worth $25.26 million more.

Investors wait Idera Pharmaceuticals Inc (NASDAQ:IDRA) to report on October, 27. its quarterly earnings Wall Street analysts expect $-0.12 earnings per share, down $0.02 or 20.00 % from last year’s $-0.1 same quarter earnings. Idera Pharmaceuticals Inc’s Wall Street analysts see -14.29 % EPS growth, taking into account the $-0.14 EPS reproted in the previous quarter,

Idera Pharmaceuticals Inc (NASDAQ:IDRA) Ratings Coverage

Among 3 analysts covering Idera Pharma (NASDAQ:IDRA), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Idera Pharma had 4 analyst reports since January 6, 2016 according to SRatingsIntel. The company was maintained on Wednesday, February 1 by Wedbush. The firm has “Outperform” rating given on Wednesday, January 6 by Wedbush. The stock of Idera Pharmaceuticals Inc (NASDAQ:IDRA) earned “Buy” rating by Piper Jaffray on Monday, September 11.

More important recent Idera Pharmaceuticals Inc (NASDAQ:IDRA) news were published by: Nasdaq.com which released: “Idera Pharmaceuticals (IDRA) Jumps: Stock Rises 14.4%” on September 12, 2017, also Fool.com published article titled: “Here’s Why Idera Pharmaceuticals, Inc. Is Surging Today”, Seekingalpha.com published: “Idera Pharmaceuticals: This ESMO Winner Is A Buy” on September 15, 2017. More interesting news about Idera Pharmaceuticals Inc (NASDAQ:IDRA) was released by: Globenewswire.com and their article: “Idera Pharmaceuticals Presents Pre-Clinical Data from IMO-2125 Treatment in …” with publication date: September 08, 2017.

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The company has market cap of $315.72 million. The Firm utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor targeting technology and third-generation antisense (3GA) technology. It currently has negative earnings. Using TLR technology, the Company creates synthetic oligonucleotide drug candidates to act by modulating the activity of specific TLRs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: